Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment

Journal of Crohn's and Colitis

Volumn 8, Issue 8, 2014, Pages 881-889

  Marits, Per ^a   Landucci, Laura ^a   Sundin, Ulf ^a   Davidsdottir, Loa ^a   Nilsson, Jakob ^a   Befrits, Ragnar ^a   Wikström, Ann Charlotte ^a   Eberhardson, Michael ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antibodies towards infliximab; Crohn's disease; Drug monitoring; Serum infliximab; Trough levels; Ulcerative colitis

Indexed keywords

ALBUMIN ANTIBODY; C REACTIVE PROTEIN; CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ALBUMIN; AZATHIOPRINE; DRUG ANTIBODY; MYCOPHENOLATE MOFETIL; ANTIBODY; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DRUG BLOOD LEVEL; DRUG INFUSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; ULCERATIVE COLITIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE EXACERBATION; HARVEY BRADSHAW INDEX; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COLITIS, ULCERATIVE; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84904465720     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.01.009     Document Type: Article

References (21)

1. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet May 4 2002, 359(9317):1541-1549. (PubMed PMID: 12047962).
2. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med Dec 8 2005, 353(23):2462-2476. (PubMed PMID: 16339095).
3. Talley N.J., Abreu M.T., Achkar J.P., Bernstein C.N., Dubinsky M.C., Hanauer S.B., et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol Apr 2011, 106(Suppl. 1):S2-S25. (quiz S6. PubMed PMID: 21472012).
4. Baert F., Noman M., Vermeire S., Van Assche G., DH G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med Feb 13 2003, 348(7):601-608. (PubMed PMID: 12584368).
5. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol Jul 2004, 2(7):542-553. (PubMed PMID: 15224278).
6. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med Feb 26 2004, 350(9):876-885. (PubMed PMID: 14985485).
7. Ben-Horin S., Yavzori M., Katz L., Kopylov U., Picard O., Fudim E., et al. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut Jan 2011, 60(1):41-48. (PubMed PMID: 20519742).
8. Imaeda H., Andoh A., Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol Feb 2012, 47(2):136-143. (PubMed PMID: 21953314).
9. Ordas I., Mould D.R., Feagan B.G., Sandborn W.J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther Apr 2012, 91(4):635-646. (PubMed PMID: 22357456).
10. Pariente B., Pineton de Chambrun G., Krzysiek R., Desroches M., Louis G., De Cassan C., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis Jul 2012, 18(7):1199-1206. (PubMed PMID: 22127789).
11. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol Oct 2006, 4(10):1248-1254. (PubMed PMID: 16931170).
12. Nanda K.S., Cheifetz A.S., Moss A.C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol Jan 2013, 108(1):40-47. (quiz 8. PubMed PMID: 23147525. Pubmed Central PMCID: 3561464).
13. Seow C.H., Newman A., Irwin S.P., Steinhart A.H., Silverberg M.S., Greenberg G.R. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut Jan 2010, 59(1):49-54. (PubMed PMID: 19651627).
14. Vande Casteele N., Gils A., Singh S., Ohrmund L., Hauenstein S., Rutgeerts P., et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol Feb 19 2013, 108:962-971. (PubMed PMID: 23419382).
15. Colombel J.F., Feagan B.G., Sandborn W.J., Van Assche G., Robinson A.M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis Feb 2012, 18(2):349-358. (PubMed PMID: 22021134).
16. Afif W., Loftus E.V., Faubion W.A., Kane S.V., Bruining D.H., Hanson K., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol May 2010, 105(5):1133-1139. (PubMed PMID: 20145610).
17. Louis E., Mary J.Y., Vernier-Massouille G., Grimaud J.C., Bouhnik Y., Laharie D., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology Jan 2012, 142(1):63-70. (e5; quiz e31. PubMed PMID: 21945953).
18. Candon S., Mosca A., Ruemmele F., Goulet O., Chatenoud L., Cezard J.P. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol Jan 2006, 118(1):11-19. (PubMed PMID: 16125467).
19. Mulleman D., Chu Miow Lin D., Ducourau E., Emond P., Ternant D., Magdelaine-Beuzelin C., et al. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit Apr 2010, 32(2):232-236. (PubMed PMID: 20216124).
20. Ternant D., Mulleman D., Degenne D., Willot S., Guillaumin J.M., Watier H., et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit Apr 2006, 28(2):169-174. (PubMed PMID: 16628126).
21. Ben-Horin S., Waterman M., Kopylov U., Yavzori M., Picard O., Fudim E., et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol Apr 2013, 11(4):444-447. (PubMed PMID: 23103905).